For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Write-off Loss on Trade Rights Related to Consolidated Subsidiary Plexxikon Inc.’s Anticancer Agent Zelboraf

Tokyo, Japan (April 28, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will book an write-off loss on trade rights related to consolidated subsidiary Plexxikon Inc.’s anticancer agent Zelboraf. Details are as follows.

 

1. Details of write-off loss

(1)   Date of loss

April 28, 2015

(2)   Reason for loss

A decision was made to post an write-off loss on trade rights related to anticancer agent Zelboraf, owned by Plexxikon Inc., a consolidated subsidiary of Daiichi Sankyo, based on an examination of future recoverability following an observable decline in profitability.

(3)   Impact on consolidated financial results

Daiichi Sankyo will book an write-off loss of \35 billion under cost of sales in the consolidated financial results for fiscal 2014 (IFRS).

 

2. Outline of subsidiary

Company name: Plexxikon Inc.

Location: 91 Bolivar Drive, Berkeley, CA 94710, USA

Representative: Gideon Bollag, Ph.D., Chief Executive Officer

Business description: Research and development focused on cancer, inflammation, cardio-renal disease, and the central nervous system

Paid-in-capital: US $1.00